Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.0%

260 terminated/withdrawn out of 2900 trials

Success Rate

87.6%

+1.1% vs industry average

Late-Stage Pipeline

7%

207 trials in Phase 3/4

Results Transparency

46%

839 of 1831 completed trials have results

Key Signals

406 recruiting839 with results164 terminated96 withdrawn

Enrollment Performance

Analytics

N/A
1357(59.1%)
Phase 2
352(15.3%)
Phase 1
316(13.8%)
Phase 4
123(5.4%)
Phase 3
84(3.7%)
Early Phase 1
66(2.9%)
2298Total
N/A(1357)
Phase 2(352)
Phase 1(316)
Phase 4(123)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2900)

Showing 20 of 2900 trials
NCT06615050Phase 3Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Role: collaborator

NCT07438041Not ApplicableNot Yet Recruiting

Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services

Role: collaborator

NCT07154719Phase 4Recruiting

GLP-1R Actions on Muscle and the Skeleton

Role: collaborator

NCT07177846Not ApplicableNot Yet Recruiting

LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer

Role: collaborator

NCT07002554Phase 2Enrolling By Invitation

Bright Light Therapy for Depressed Geriatric Inpatients

Role: collaborator

NCT02711709Completed

Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty

Role: collaborator

NCT04592250Active Not Recruiting

Financial Toxicity in Cancer Patients

Role: collaborator

NCT04247191Not ApplicableTerminated

Parent Intervention to Reduce College Student Drinking and Consequences

Role: collaborator

NCT07303894Phase 2Recruiting

A Study of Isoquercetin in People With Ovarian Cancer

Role: collaborator

NCT06323824Phase 4Recruiting

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

Role: collaborator

NCT04895306Phase 2Completed

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

Role: collaborator

NCT07532252Phase 2Not Yet Recruiting

Daridorexant for Alcohol Use Disorder

Role: collaborator

NCT04396808Not ApplicableActive Not Recruiting

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Role: collaborator

NCT00260585Recruiting

Esophageal Cancer Risk Registry

Role: collaborator

NCT06691217Phase 2Recruiting

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Role: collaborator

NCT07390955Phase 1Recruiting

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

Role: collaborator

NCT06753669Not ApplicableRecruiting

Mothers' Action Project for Child Health

Role: collaborator

NCT05639426Not ApplicableEnrolling By Invitation

Preventing Youth Violence Through Building Equitable Communities

Role: collaborator

NCT05129020Not ApplicableActive Not Recruiting

Neurostimulation to Improve NOWS Outcomes

Role: collaborator

NCT05471076Phase 1Active Not Recruiting

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

Role: collaborator